Pipeline Watch: Phase III Progress With Roche's Baloxavir, Pfizer's Tanezumab And Takeda's Vedolizumab
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
Lilly’s CVOT Success With Trulicity Causes Bullish Outlook For Diabetes Franchise
Lilly reported strong sales growth for many of its recently launched products, but news of the potentially differentiating REWIND cardiovascular outcomes trial data dominated the pharma’s third quarter earnings call.
Forte Biosciences' Future In Doubt After Only Product Fails
Forte Biosciences’ attempts to use a new approach to treating inflammatory skin disease using a topical live biotherapeutic, FB-401, have come to a crashing halt at Phase II. Where the company goes next remains to be seen.